Advertisement Yabao, Changzhou Le Sun Pharmaceuticals to develop early-stage cancer drugs - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Yabao, Changzhou Le Sun Pharmaceuticals to develop early-stage cancer drugs

China-based Yabao Pharmaceutical has entered into a strategic partnership with Changzhou Le Sun Pharmaceuticals to co-develop Le Sun's leading PLK/PI3K dual inhibitor LS-008, which currently is under pre-clinical development.

Under the deal, Yabao secured exclusive rights to develop and commercialize LS-008 in China while Le Sun retains majority of exclusive rights in all other markets.

Both the firms will jointly determine the strategic development plan, which will be performed primarily by Yabao in China under global GLP, GMP and GCP standards.

According to the companies, the partnership helps in accelerating the development of an oncology compound in China for the globe, by leveraging the complementary strengths of a Chinese pharmaceutical firm and a world-class medicinal chemistry and drug discovery expertise.

Yabao Pharmaceutical president of R&D Peng Wang said PLK/PI3K dual inhibition represents a new and promising approach to developing new drugs for several cancers, with the most advanced compounds currently in phase III global development.

"We strongly believe LS-008 has potential to be best-in-class," Wang said.

"This ground-breaking partnership with Changzhou Le Sun Pharmaceuticals is an important sign of Yabao’s growing commitment to partner the best science and leverage Yabao’s strong clinical and regulatory capabilities to bring novel pharmaceuticals to patients suffering from serious diseases in China and in the world."

Changzhou Le Sun Pharmaceuticals founder and president professor Shudong Wang said: "Working together we are building on the strengths of both parties to develop potential new drug and help patients globally."